Literature DB >> 8578798

Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial.

N R Boulter1, E J Glass, P A Knight, L Bell-Sakyi, C G Brown, R Hall.   

Abstract

A C terminal fragment (SR1) of SPAG-1, a sporozoite surface antigen of Theileria annulata, has been expressed as a fusion protein in the e1 loop of hepatitis B core antigen (HBcAg). This recombinant antigen (HBcAg-SR1) is produced in the form of self-assembling polyhedral particles which have been visualised under the electron microscope. Cattle immunised with HBcAg-SR1 produced high titres of neutralising antibodies. A significant T cell response to both the HBcAg and SR1 determinants was observed but evidence of a T suppressor determinant in SR1 was also revealed. Immunised cattle showed some evidence of protection to sporozoite challenge as assessed by severity of the disease. The significance of these findings for the development of a sub-unit vaccine against T. annulata is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578798     DOI: 10.1016/0264-410x(95)00026-w

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

Authors:  P A Kratz; B Böttcher; M Nassal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Diminished IL-2 responses and alteration of CD2 expression on CD8+ T cells are associated with a lack of cytotoxic T cell responses during Theileria annulata infection.

Authors:  A K Nichani; S C Craigmile; R L Spooner; J D Campbell
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Molecular genetic characterization and subcellular localization of a putative Theileria annulata membrane protein.

Authors:  Ilka Schneider; Daniel Haller; Ulrike Seitzer; Doreen Beyer; Jabbar S Ahmed
Journal:  Parasitol Res       Date:  2004-10-14       Impact factor: 2.289

4.  Functional expression of a cattle MHC class II DR-like antigen on mouse L cells.

Authors:  D C Fraser; S Craigmile; J D Campbell; R A Oliver; D J Brown; G C Russell; R L Spooner; E J Glass
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

Review 5.  Molecular tools-advances, opportunities and prospects for the control of parasites of veterinary importance.

Authors:  Sachin Kumar; Snehil Gupta; Aquil Mohmad; Ashutosh Fular; B C Parthasarathi; Ashok Kumar Chaubey
Journal:  Int J Trop Insect Sci       Date:  2020-07-29       Impact factor: 0.774

Review 6.  Approaches to vaccination against Theileria parva and Theileria annulata.

Authors:  V Nene; W I Morrison
Journal:  Parasite Immunol       Date:  2016-12       Impact factor: 2.280

Review 7.  Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-24

Review 8.  Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines.

Authors:  G P Lomonossoff; J E Johnson
Journal:  Curr Opin Struct Biol       Date:  1996-04       Impact factor: 6.809

9.  Synergistic Effect of Two Nanotechnologies Enhances the Protective Capacity of the Theileria parva Sporozoite p67C Antigen in Cattle.

Authors:  Anna Lacasta; Karishma T Mody; Ine De Goeyse; Chengzhong Yu; Jun Zhang; James Nyagwange; Stephen Mwalimu; Elias Awino; Rosemary Saya; Thomas Njoroge; Robert Muriuki; Nicholas Ndiwa; Elisabeth Jane Poole; Bing Zhang; Antonino Cavallaro; Timothy J Mahony; Lucilla Steinaa; Neena Mitter; Vishvanath Nene
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.422

10.  Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.

Authors:  Upasana Arora; Poornima Tyagi; Sathyamangalam Swaminathan; Navin Khanna
Journal:  J Nanobiotechnology       Date:  2012-07-13       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.